Treatment of Fibrous Dysplasia of Bone with Growth Hormone Excess (FD/MAS)
When fibrous dysplasia of bone occurs alongside growth hormone excess as part of FD/MAS, the clinical picture extends beyond skeletal disease and requires a targeted endocrine management approach with defined treatment goals.
Clinical Scenario
This protocol is indicated for patients with fibrous dysplasia of bone in the setting of growth hormone excess associated with FD/MAS. The coexistence of growth hormone excess determines both the choice of intervention and the criteria used to evaluate response.
Treatment Approach & Goals
First-line medical therapy draws on a specific class of agents acting on somatostatin receptors. The treatment goal is to bring IGF-1 into a defined target range as the primary marker of hormonal control.
The complete regimen — including agent selection, dosing, monitoring schedule, and escalation criteria — is available in the full structured protocol below.
References
Somatostatin analogues are first line therapies with second line options including pegvisomant, alone or in combination with octreotide or lanreotide at the discretion of the treating physician.
The treatment goals are to achieve an IGF-1 Z-score between −2 and +1.
DOI: 10.1186/s13023-019-1102-9
View source ↗